Unusual gingival presentation of post-transplantation lymphoproliferative disorder: a case report and review of the literature.
Post-transplantation lymphoproliferative disorder is a well-documented complication of solid organ or bone marrow transplantation. Histologically, it is characterized by an abnormal proliferation of lymphocytes, which can range from benign B-cell hyperplasia to malignant lymphoma. Non-Hodgkin's lymphoma (NHL) is associated with several risk factors, such as congenital or acquired immunodeficiency states, autoimmune disorders, and infectious agents (eg, Epstein-Barr virus). Primary sites of presentation in the head and neck are Waldeyer's ring, paranasal sinuses, salivary glands, the oral cavity, and the larynx. Clinical appearance of gingival NHL varies but is usually found to be an asymptomatic gingival enlargement or mass resembling a pyogenic granuloma. We present a patient with a gingival ulceration that was subsequently diagnosed as Epstein-Barr virus malignant lymphoma resulting from the immunosuppression needed to prevent graft-versus-host disease after bone marrow transplantation.
Raut
A
A
Memorial Sloan-Kettering Cancer Center, Dental Service, Department of Surgery, New York, NY 10021, USA.
Huryn
J
J
Pollack
A
A
Zlotolow
I
I
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002051:Burkitt Lymphoma / Q000209:etiology / Q000473:pathology* / Q000628:therapy; D003937:Diagnosis, Differential; D005887:Gingival Neoplasms / Q000209:etiology / Q000473:pathology* / Q000628:therapy; D006086:Graft vs Host Disease / Q000150:complications / Q000209:etiology; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D016403:Lymphoma, Large B-Cell, Diffuse / Q000209:etiology / Q000473:pathology* / Q000628:therapy; D008297:Male; D009367:Neoplasm Staging; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab